PTC Therapeutics, Inc. Operating Cash Flow
PTC Therapeutics, Inc. (PTCT) reported Operating Cash Flow of $70.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $129.11M.
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$59.04M, a 106.79% decline year-over-year.
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$34.27M.
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$66.30M.
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $711.20M.
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$107.69M.
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$158.42M.
- PTC Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$356.65M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $129.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $70.07M 10-Q · filed 2026-07-30 | $35.80M derived: sum of 3 quarters · filed 2026-07-30 | -$30.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$59.04M 10-Q · filed 2026-05-07 | -$93.31M derived: sum of 2 quarters · filed 2026-05-07 | -$159.62M derived: sum of 3 quarters · filed 2026-05-07 | -$217.95M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$34.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$100.57M derived: sum of 2 quarters · filed 2026-02-19 | -$158.91M derived: sum of 3 quarters · filed 2026-07-30 | $711.20M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$66.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$124.63M derived: sum of 2 quarters · filed 2026-07-30 | $745.47M 10-Q · filed 2025-11-04 | $715.47M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$58.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $811.77M 10-Q · filed 2026-07-30 | $781.77M derived: sum of 3 quarters · filed 2026-07-30 | $704.77M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $870.10M 10-Q · filed 2026-05-07 | $840.10M derived: sum of 2 quarters · filed 2026-05-07 | $763.11M derived: sum of 3 quarters · filed 2026-05-07 | $691.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$107.00M derived: sum of 2 quarters · filed 2026-02-19 | -$178.45M derived: sum of 3 quarters · filed 2026-02-19 | -$107.69M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$76.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$148.44M derived: sum of 2 quarters · filed 2025-11-04 | -$77.68M 10-Q · filed 2025-11-04 | -$177.97M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$71.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$692.00K 10-Q · filed 2025-08-07 | -$100.98M derived: sum of 3 quarters · filed 2026-02-19 | -$115.50M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $70.76M 10-Q · filed 2025-05-06 | -$29.53M derived: sum of 2 quarters · filed 2026-02-19 | -$44.05M derived: sum of 3 quarters · filed 2026-02-19 | -$58.17M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$100.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$114.81M derived: sum of 2 quarters · filed 2026-02-19 | -$128.93M derived: sum of 3 quarters · filed 2026-02-19 | -$158.42M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$14.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$28.64M derived: sum of 2 quarters · filed 2024-11-07 | -$58.13M 10-Q · filed 2024-11-07 | -$224.09M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$14.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$43.61M 10-Q · filed 2024-08-08 | -$209.57M derived: sum of 3 quarters · filed 2025-02-27 | -$247.62M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$29.49M 10-Q · filed 2024-04-25 | -$195.45M derived: sum of 2 quarters · filed 2025-02-27 | -$233.50M derived: sum of 3 quarters · filed 2025-02-27 | -$288.74M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$165.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$204.01M derived: sum of 2 quarters · filed 2025-02-27 | -$259.25M derived: sum of 3 quarters · filed 2025-02-27 | -$356.65M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$38.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$93.29M derived: sum of 2 quarters · filed 2023-10-26 | -$190.69M 10-Q · filed 2023-10-26 | -$259.53M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$55.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$152.65M 10-Q · filed 2023-08-03 | -$221.49M derived: sum of 3 quarters · filed 2024-02-29 | -$272.68M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$97.40M 10-Q · filed 2023-04-27 | -$166.24M derived: sum of 2 quarters · filed 2024-02-29 | -$217.43M derived: sum of 3 quarters · filed 2024-02-29 | -$248.58M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$68.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$120.03M derived: sum of 2 quarters · filed 2024-02-29 | -$151.18M derived: sum of 3 quarters · filed 2024-02-29 | -$251.33M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$51.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$82.33M derived: sum of 2 quarters · filed 2022-10-27 | -$182.49M 10-Q · filed 2022-10-27 | -$246.86M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$31.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$131.30M 10-Q · filed 2022-08-04 | -$195.67M derived: sum of 3 quarters · filed 2023-02-21 | -$169.01M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$100.16M 10-Q · filed 2022-05-03 | -$164.52M derived: sum of 2 quarters · filed 2023-02-21 | -$137.86M derived: sum of 3 quarters · filed 2023-02-21 | -$212.67M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | -$64.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$37.71M derived: sum of 2 quarters · filed 2023-02-21 | -$112.52M derived: sum of 3 quarters · filed 2023-02-21 | -$194.07M 10-K · filed 2023-02-21 |
| 2020-09-30 | $26.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$48.15M derived: sum of 2 quarters · filed 2021-10-28 | -$129.71M 10-Q · filed 2021-10-28 | -$139.91M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$74.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$156.36M 10-Q · filed 2021-07-29 | -$166.57M derived: sum of 3 quarters · filed 2022-02-22 | -$182.07M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | -$81.55M 10-Q · filed 2021-05-04 | -$91.76M derived: sum of 2 quarters · filed 2022-02-22 | -$107.26M derived: sum of 3 quarters · filed 2022-02-22 | -$137.78M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$10.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$25.71M derived: sum of 2 quarters · filed 2022-02-22 | -$56.23M derived: sum of 3 quarters · filed 2022-02-22 | -$98.64M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$15.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$46.02M derived: sum of 2 quarters · filed 2020-10-29 | -$88.43M 10-Q · filed 2020-10-29 | -$103.58M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$30.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$72.93M 10-Q · filed 2020-08-05 | -$88.07M derived: sum of 3 quarters · filed 2021-02-25 | -$84.70M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$42.41M 10-Q · filed 2020-04-30 | -$57.55M derived: sum of 2 quarters · filed 2021-02-25 | -$54.17M derived: sum of 3 quarters · filed 2021-02-25 | -$54.17M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$11.77M derived: sum of 2 quarters · filed 2021-02-25 | -$11.76M derived: sum of 3 quarters · filed 2021-02-25 | -$27.64M 10-K · filed 2021-02-25 |
| 2018-09-30 | $3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $3.38M derived: sum of 2 quarters · filed 2019-10-30 | -$12.50M 10-Q · filed 2019-10-30 | $8.79M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$15.88M 10-Q · filed 2019-08-06 | $5.41M derived: sum of 3 quarters · filed 2020-03-02 | -$10.36M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$15.88M 10-Q · filed 2019-05-02 | $5.41M derived: sum of 2 quarters · filed 2020-03-02 | -$10.36M derived: sum of 3 quarters · filed 2020-03-02 | $2.96M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $21.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $5.52M derived: sum of 2 quarters · filed 2020-03-02 | $18.84M derived: sum of 3 quarters · filed 2020-03-02 | -$10.06M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$15.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$2.45M derived: sum of 2 quarters · filed 2018-11-05 | -$31.35M 10-Q · filed 2018-11-05 | -$44.67M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $13.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$15.58M 10-Q · filed 2018-08-07 | -$28.90M derived: sum of 3 quarters · filed 2019-03-01 | -$52.98M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$28.90M 10-Q · filed 2018-05-09 | -$42.22M derived: sum of 2 quarters · filed 2019-03-01 | -$66.30M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2016-12-31 | -$13.32M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$37.39M derived: sum of 2 quarters · filed 2019-03-01 | -$103.57M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$24.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$90.25M 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | -$66.17M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$124.34M 10-K · filed 2018-03-06 | |||
| 2014-12-31 | -$57.27M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |